Osser, DN, Sigadel, R. Short-term inpatient pharmacotherapy of schizophrenia. Harv Rev Psychiatry
2001; 9: 89–104.
Alderfer, BS, Allen, MH. Treatment of agitation in bipolar disorder across the life cycle. J Clin Psychiatry
2003; 64 (suppl 4): 3–9.
Battaglia, J. The treatment of acute agitation in schizophrenia. CNS Spectr
2007; 12 (suppl 11): 4–5.
Currier, GW, Trenton, A. Pharmacological treatment of psychotic agitation. CNS Drugs
2002; 16: 219–28.
Yildiz, A, Sachs, GS, Turgay, A. Pharmacological management of agitation in emergency settings. Emerg Med J
2003; 20: 339–46.
Currier, GW, Allen, MH, Bunney, EB, Daniel, DG, Francis, A, Jagoda, A, et al. Standard therapies for acute agitation. J Emerg Med
2004; 27 (suppl 4): s9–12.
Battaglia, J. Pharmacological management of acute agitation. Drugs
2005; 65: 1207–22.
Citrome, L. Interventions for the treatment of acute agitation. CNS Spectr
2007; 12 (suppl 11): 8–12.
Nordstrom, K, Allen, MH. Managing the acutely agitated and psychotic patient. CNS Spectr
2007; 12 (suppl 17): 5–11.
Zimbroff, DL. Pharmacological control of acute agitation: focus on intramuscular preparations. CNS Drugs
2008; 22: 199–212.
Allen, MH, Currier, GW, Hughes, DH, Reyes-Harde, M, Docherty, JP. The Expert Consensus Guideline Series. Treatment of behavioral emergencies. Postgrad Med
2001; : 1–88.
Breier, A, Meehan, K, Birkett, M, David, S, Ferchland, I, Sutton, V, et al. A double-blind, placebo-controlled dose-response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia. Arch Gen Psychiatry
2002; 59: 441–8.
Tran-Johnson, TK, Sack, DA, Marcus, RN, Auby, P, McQuade, RD, Oren, DA. Efficacy and safety of intramuscular aripiprazole in patients with acute agitation: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry
2007; 68: 111–9.
Wright, P, Birkett, M, David, SR, Meehan, K, Ferchland, I, Alaka, KJ, et al. Double-blind, placebo-controlled comparison of intramuscular olanzapine and intramuscular haloperidol in the treatment of acute agitation in schizophrenia. Am J Psychiatry
2001; 158: 1149–51.
Battaglia, J, Lindborg, SR, Alaka, K, Meehan, K, Wright, P. Calming versus sedative effects of intramuscular olanzapine in agitated patients. Am J Emerg Med
2003; 21: 192–8.
Heel, RC, Brogden, RN, Speight, TM, Avery, GS. Loxapine: a review of its pharmacological properties and therapeutic efficacy as an antipsychotic agent. Drugs
1978; 15: 198–217.
Chakrabarti, A, Bagnall, A, Chue, P, Fenton, M, Palaniswamy, V, Wong, W, et al. Loxapine for schizophrenia. Cochrane Database Syst Rev
2007; 4: CD001943.
Paprocki, J, Versiani, M. A double-blind comparison between loxapine and haloperidol by parenteral route in acute schizophrenia. Curr Ther Res Clin Exp
1977; 21: 80–100.
Fruensgaard, K, Korsgaard, S, Jorgensen, H, Jensen, K. Loxapine versus haloperidol parenterally in acute psychosis with agitation. A double-blind study. Acta Psychiatr Scand
1977; 56: 256–64.
Dubin, WR, Weiss, KJ. Rapid tranquilization: a comparison of thiothixene with loxapine. J Clin Psychiatry
1986; 47: 294–7.
Gaussares, C, Gerard, H, Bosc, M. Interest in injectable Loxapine for severe agitation. Inf Psychiatr
1989; 69: 656–60.
Bourdinard, V, Pochard, F. Survey of management methods for patients in a state of agitation at admissions and emergency departments in France. Encephale
2003; 29: 89–98.
Glazer, WM. Does loxapine have “atypical” properties? Clinical evidence. J Clin Psychiatry
1999; 60 (suppl 10): 42–6.
Spyker, DA, Munzar, P, Cassella, JV. Pharmacokinetics of loxapine following inhalation of a thermally generated aerosol in healthy volunteers. J Clin Pharmacol
2010; 50: 169–79.
Cassella, J, Fishman, R, Spyker, D. AZ-004 Study Group. Inhaled loxapine rapidly improves acute agitation in schizophrenic patients. In Proceedings of the 162nd Annual Meeting of the American Psychiatric Association 2009: New Research Abstracts and Syllabus. . Curran Associates, 2010.
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorder (4th edn) (DSM–IV). APA, 1994.
Kay, SR, Fiszbein, A, Opler, LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull
1987; 13: 261–76.
Kay, SR. Significance of the positive-negative distinction in schizophrenia. Schizophr Bull
1990; 16: 635–52.
Rabinowitz, JD, Lloyd, PM, Munzar, P, Myers, DJ, Cross, S, Damani, R, et al. Ultrafast absorption of amorphous pure drug aerosols via deep lung inhalation. J Pharm Sci
2006; 95: 2438–51.
Rabinowitz, JD, Wensley, M, Lloyd, P, Myers, D, Shen, W, Lu, A, et al. Fast onset medications through thermally generated aerosols. J Pharmacol Exp Ther
2004; 309: 769–75.
Guy, W. ECEU Assessment Manual for Psychopharmacology – Revised: 218–22. US Department of Health, Education, and Welfare, 1976.
Meehan, KM, Wang, H, David, SR, Nisivoccia, JR, Jones, B, Beasley, CM Jr, et al. Comparison of rapidly acting intramuscular olanzapine, lorazepam, and placebo: a double-blind, randomized study in acutely agitated patients with dementia. Neuropsychopharmacol
2002; 26: 494–504.
Buckley, PF. The role of typical and atypical antipsychotic medications in the management of agitation and aggression. J Clin Psychiatry
1999; 60 (suppl 10): 52–60.
Allen, MH, Currier, GW. Use of restraints and pharmacotherapy in academic psychiatric emergency services. Gen Hosp Psychiatry
2004; 26: 42–9.